
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:GSK
CUSIPN/A
Phone44-20-8047-5000
Debt
Debt-to-Equity Ratio4.09%
Current Ratio0.60%
Quick Ratio0.39%
Price-To-Earnings
Trailing P/E Ratio13.89
Forward P/E Ratio13.70
P/E Growth2.13
Sales & Book Value
Annual Sales$38.89 billion
Price / Sales2.55
Cash Flow$3.8388 per share
Price / Cash10.42
Book Value$1.81 per share
Price / Book22.10
Profitability
EPS (Most Recent Fiscal Year)$2.88
Net Income$1.97 billion
Net Margins4.97%
Return on Equity130.63%
Return on Assets10.28%
Miscellaneous
Employees99,827
Outstanding Shares2,479,430,000